HumanZyme® Launches New XKine™ Recombinant Protein Line Expanding Reagents For Stem Cell Research and Regenerative Medicine Applications

Share Article

HumanZyme announces new XKine product line, expanding their recombinant human protein offering for stem cell and regenerative therapy researchers.

"The new XKine products allow customers to source more cytokines and growth factors from HumanZyme without the need for a 3rd party supplier."

HumanZyme Inc., a leading supplier of novel human proteins and growth factors to academic and biopharmaceutical customers enabling stem cell research and regenerative therapy applications, today announced the launch of the new XKine™ product line broadening the company's product offering. The new XKine human recombinant proteins are manufactured utilizing E.coli, Insect, or Chinese Hamster Ovary (CHO) host cell lines, expanding the number of research applications supported by HumanZyme.

“The new XKine products are priced competitively and selected carefully to support current pathway analysis, allowing our customers to purchase these products from HumanZyme, without the need to go to a 3rd party supplier as previously required,” said Scott Coleridge, CEO at HumanZyme. The new XKine recombinant human protein line includes Activin-B, Adiponectin, IL-1 alpha, INF-gamma, INF-beta, IL-5, IL8(CxXL8), IL-11, IL-15, IL-13, IL-16, IL-17b/d/e, IL-34, IL35, DKK, CT-1, IGF-1, Neurturin, PDGF-BB, Rantes(CCL5), sCD40 ligand, sTrail/apo2L, BDNF, GDNF, CTGF, EGF, FGF-basic, LIF, BMP-3, BMP-5, BMP-13, Prolactin, Relaxin 2, TNF-beta, Sonic Hedgehog, and FGF-acidic.

For more information, see our list of new XKine products.

About HumanZyme, Inc.

HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications, such as disulfide bonds and glycosylation. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide—from academic and government research institutions to biotechnology and pharmaceutical companies. For more information, visit http://www.humanzyme.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Wiggins
Visit website